SCHEMBL5227563

SCHEMBL5227563

COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)N3CCN(c4ccccn4)CC3)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
ALDH1A1 P00352 12/20 0.47
KDM4E B2RXH2 4/20 0.47
HSD17B10 Q99714 2/20 0.47
USP2 O75604 1/20 0.47
TSHR P16473 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
CYP3A4 P08684 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 2/20 0.45
MAPK1 P28482 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CDK5 Q00535 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262635 1.00 MAPT (0.47) MAPTALDH1A1KDM4EHSD17B10USP2
SCHEMBL5262638 0.92 ALDH1A1 (0.41) MAPTALDH1A1KDM4EHSD17B10USP2
SCHEMBL5262632 0.88 ALDH1A1 (0.38) MAPTALDH1A1KDM4EHSD17B10USP2
SCHEMBL14432776 0.84 TP53 (0.47) ALDH1A1CYP1A2L3MBTL1LMNAHPGD
SCHEMBL14432801 0.81 CYP1A2 (0.41) MAPTCYP1A2L3MBTL1LMNAKMT2A
SCHEMBL6264205 0.81 ALDH1A1 (0.40) MAPTALDH1A1KDM4EHSD17B10USP2
SCHEMBL5232381 0.81 CCR5 (0.40) CYP1A2
SCHEMBL5229698 0.80 TP53 (0.42) CYP1A2
SCHEMBL5229557 0.80 HPGD (0.46) MAPTALDH1A1KDM4EHSD17B10TSHR
SCHEMBL14433142 0.79 ALDH1A1 (0.47) ALDH1A1CYP1A2L3MBTL1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP claimed
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors DSPI LIMITED (GB) 2006-06-22 US claimed
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP disclosed
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP disclosed
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors DSPI LIMITED (GB) 2006-06-22 US disclosed
EP-1581528-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS Metris Therapeutics Limited (GB) 2005-10-05 EP disclosed
WO-2004058750-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO disclosed
WO-2004058751-A1 PIPERIDINYL-THIAZOLE CARBOXAMIDE DERIVATIVES FOR ALTERING VASCULAR TONE METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors PGF, FLT1, VEGFA MAPT 1692/4885ALDH1A1 101/4885KDM4E 3265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.